I agree Sandy's presentation was excellent.
I thought the third panel discussion on immuno-oncology was very informative. Oz Azam (CEO of Tmunity, formerly w/Novartis) made a point that older gene editing technology is far from obsolete because of continued innovation (didn't mention Sangamo by name, but I bet that was who he was thinking of). Also he pointed out that allogeneic is an attainable goal and a logical next generation to follow autologous CAR-T. Imo, only a matter of time before Sangamo partners in immuno-oncology with the likes of Tmunity, UPenn, Novartis.